Litcius/Paper detail

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena Perna, Sherilyn A. Tuazon, San-San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda

2023The Lancet198 citationsDOIOpen Access PDF

Topics & Concepts

MedicineChronic lymphocytic leukemiaOpen labelLymphomaOncologyInternal medicineLeukemiaClinical trialChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchPhagocytosis and Immune Regulation
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study | Litcius